Semaglutide-associated bullous pemphigoid
Clayton P. Burruss, Jordan Jones, Jyoti B. Burruss
Abstract
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by intensely pruritic urticarial plaques and bullae of the skin and, to a lesser extent, the mucosa.1,2 While many cases of BP are determined to be idiopathic, the incidence of BP with various medications resulting in drug-associated bullous pemphigoid (DABP) is on the rise.3 Glucagon-like peptide-1 (GLP-1) agonist-associated BP has been previously reported after administration of dulaglutide.4 Here we report a unique case of BP attributed to semaglutide, another medication in the GLP-1 agonist class.
Topics & Concepts
Bullous pemphigoidMedicineSemaglutidePemphigoidAgonistDermatologyExenatideInternal medicineImmunologyEndocrinologyDiabetes mellitusReceptorType 2 diabetesLiraglutideAntibodyAutoimmune Bullous Skin DiseasesCoagulation, Bradykinin, Polyphosphates, and AngioedemaUrticaria and Related Conditions